Clay Siegall resurfaces as CEO of biotech start-up

23 March 2023

Clay Siegall is leaping back into the biotech world as chief executive and president of Morphimmune, a pre-clinical biotechnology company focused on developing targeted oncology therapeutics based in Seattle, USA.

Dr Siegall previously served as the CEO and president of Seagen (Nasdaq: SGEN), which he co-founded in July 1997 as Seattle Genetics, and is now the subject of a $43 billion takeover by Pfizer (NYSE: PFE). Under his nearly 25 years of leadership, Seagen became the world leader in ADC therapeutics. Dr Siegall resigned as Seagen CEO and chairman in May 2022. He was arrested in April last year following an alleged domestic violence incident involving his then-wife. Prosecutors said in December that Dr Siegall would not face charges.

Prior to Seagen, Dr Siegall worked in positions of increasing responsibilities at Bristol Myers Squibb (NYSE: BMY) and the National Cancer Institute.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK